//--> //--> //-->
Toggle navigation
Logout
Change account settings
EN
DE
ES
FR
A-Z
Beta
About EconBiz
News
Thesaurus (STW)
Academic Skills
Help
EN
DE
ES
FR
My account
Logout
Change account settings
Login
Publications
Events
Your search terms
Search
Retain my current filters
~source:"econstor"
Search options
All Fields
Title
Exact title
Subject
Author
Institution
ISBN/ISSN
Published in...
Publisher
Open Access only
Advanced
Search history
My EconBiz
Favorites
Loans
Reservations
Fines
You are here:
Home
Tariffs, corruption, and other...
Similar by person
Narrow search
Delete all filters
| 1 applied filter
Year of publication
From:
To:
Subject
All
pharmaceuticals
2
FDA
1
United Kingdom (UK)
1
cigarettes
1
drug policy
1
drug safety
1
e-cigarettes
1
emerging market economies
1
fake drugs
1
generic drugs
1
global health
1
tax reform
1
more ...
less ...
Online availability
All
Free
10
Type of publication
All
Book / Working Paper
10
Type of publication (narrower categories)
All
Working Paper
10
Language
All
English
10
Author
All
Bate, Roger
10
Mathur, Aparna
5
Kallen, Cody
1
Mooney, Lorraine
1
Published in...
All
AEI Economics Working Paper
8
AEI Working Paper
2
Source
All
EconStor
OLC EcoSci
85
ECONIS (ZBW)
73
RePEc
46
Other ZBW resources
1
Showing
1
-
10
of
10
Sort
relevance
articles prioritized
date (newest first)
date (oldest first)
1
WHO's comprehensive HIV treatment failure: Will we learn the real lessons from 3 by 5?
Bate, Roger
;
Mooney, Lorraine
-
2006
Persistent link: https://www.econbiz.de/10014439222
Saved in:
2
A field study of the opioid market: Authenticity and price from pharmacy to street
Bate, Roger
-
2018
With the assistance of pain patients, the opioids oxycodone and hydrocodone were assessed from licit and illicit sources in Philadelphia and surrounding counties. Sources included brick-and-mortar pharmacies, web pharmacies operating illegally by selling products without prescriptions, other...
Persistent link: https://www.econbiz.de/10014439109
Saved in:
3
The impact of improved detection technology on drug quality: A case study of Lagos, Nigeria
Bate, Roger
;
Mathur, Aparna
-
2011
Persistent link: https://www.econbiz.de/10014439132
Saved in:
4
Corruption and medicine in Latin America: a pilot study
Mathur, Aparna
;
Bate, Roger
-
2017
Fake and substandard medicines are a significant problem in developing nations and a growing problem in developed ones, too. This study finds that corruption is strongly correlated with poor-quality drugs.
Persistent link: https://www.econbiz.de/10014439207
Saved in:
5
To vape or not to vape? Preliminary results from a qualitative survey of smokers
Mathur, Aparna
;
Bate, Roger
-
2019
A recent survey found that a higher percentage of sampled smokers had tried vaping in the UK, relative to the US, especially among those who claimed they had tried to quit smoking previously.
Persistent link: https://www.econbiz.de/10014439216
Saved in:
6
The market for inferior medicines: Comparing the price of falsified and substandard products with the legitimate medicines in emerging markets
Bate, Roger
-
2011
Persistent link: https://www.econbiz.de/10014439227
Saved in:
7
Poor countries need relief from the World Bank's 'help' on malaria
Bate, Roger
-
2006
Persistent link: https://www.econbiz.de/10014439254
Saved in:
8
Combating dangerous medicines – Differences in quality of medicines sold by small pharmacies and large chain pharmacies
Bate, Roger
-
2012
Persistent link: https://www.econbiz.de/10014439302
Saved in:
9
The perverse effect of sin taxes: The rise of illicit white cigarettes
Mathur, Aparna
;
Bate, Roger
;
Kallen, Cody
-
2017
This paper analyzes whether taxes create a price wedge between legal and illicit cigarettes and thereby affect the availability and trade of illicit whites across markets.
Persistent link: https://www.econbiz.de/10014439309
Saved in:
10
Generics substitution, bioequivalence standards, and oversight of international pharmaceutical producers: Complex issues facing the FDA
Mathur, Aparna
;
Bate, Roger
-
2015
The rules underlying the assessment of quality of generic drugs, and their bioequivalence to brand name products, have not changed significantly since the passage of the Hatch-Waxman Act in 1984. Yet the products on the market are significantly more complicated today, which may imply that two...
Persistent link: https://www.econbiz.de/10014439317
Saved in:
Results per page
10
25
50
100
250
A service of the
zbw
×
Loading...
//-->